View clinical trials related to Cancer.
Filter by:The aim of the study is to assess tolerability and activity of oxycodone and pregabalin in combination for the treatment of oncological neuropathic pain with two different strategies.
To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).
A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.
RATIONALE: A multimedia education program for family caregivers that teaches simple methods of touch and massage for the comfort of cancer patients at home may be effective in lowering stress, reducing symptoms, and improving quality of life for patients; and may improve caregiver satisfaction and self-efficacy. PURPOSE: This randomized phase II trial is studying how well multimedia instruction of caregivers in use of touch and massage works for cancer patients and their care partners.
This study is a qualitative, phenomenological research design. The research question is the lived experience of adult oncology patients undergoing chemotherapy being touched and touching. The researcher will conduct minimally-structured interviews with a set of follow-up interviews to verify interpretations and ascertain additional participant reflections on the phenomenon of touch. The purpose of this study is to describe the sensation of touch in adult oncology patients who are actively undergoing chemotherapy treatment. The primary objective is to identify the essences of multiple meanings of touch to these patients. The importance of touch in physiological development, learning patterns, and stress reduction has been demonstrated in humans and animals through years of research (Field, 2000). Based on research which indicates touch therapies provide a significant amount of symptom relief and reduction in anxiety, a growing number of hospitals and clinics are integrating massage therapy into services provided to patients in order to ameliorate many symptoms of diagnosis and/or treatment-related discomfort. Examples are the integrative medicine programs at Memorial Sloan-Kettering Cancer Center and George Washington University Medical Center which include touch therapy modalities. Research focusing on the embodied experience of sensory phenomena such as touch is important to provide the basis for more effective care. No studies to date have focused on the self-reported experience of the cancer patient with regard to what touch means to these individuals, particularly those actively in treatment with intravenous chemotherapy. The embodied sensation of touch in these people is important to understand in order to provide more effective touch-based interventions and also to increase awareness of direct care staff, including nurses, of the profound and complex effect that all forms of touch have on those who are physically and psychically vulnerable.
This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues.
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
This phase 1/2a trial is conducted in Europe. The first part of the trial is a dose escalation safety trial determining the maximum tolerated dose of rIL-21 when administered in combination with sunitinib. The second part, scheduled to start in September 2008, is a randomised 2-arm trial comparing the anti-tumour effect of rIL-21 plus sunitinib with sunitinib alone.
The purpose of this study is to see if a blood test (D-dimer) is as precise as the CT scan for the detection of clots. A pulmonary embolism is an obstruction of the blood vessels in your lungs usually due to a blood clot that travels to the lungs usually from the leg. Research has shown that the results of a specific blood test (D-dimer) can be used instead of a CT scan to diagnose clots. D-dimer is a valuable diagnostic marker in either detecting the presence of or monitoring the progress of blood clots. D-dimer assays have proven to be a beneficial diagnostic tool in the evaluation of patients with suspected pulmonary embolism (PE).
Introduction: Oral pain due to mucosal lesion is quite frequent in oncology, geriatric as well as palliative care settings. The oncology patient is mainly suffering from radio- and/or chemotherapy induced oral mucositis. The incidence of oral mucositis in oncology patients ranges from 15-40% in those receiving stomatotoxic chemotherapy or radiotherapy. The degree of mucositis is variable, but the associated pain is frequent and well documented. Nowadays, basic oral care protocols are the mainstay of preventing or reducing mucositis pain. Pain is mainly managed by systemically administered analgesia. The only pioneer work in the field of radio-or chemotherapy induced mucositis treatment with topical opioids has been done by Cerchietti in two pilot studies: one compared "magic" mouthwash (lidocaine, diphenhydramine, magnesium aluminium hydroxide) with morphine mouthwash in a randomized trial; the other compared 1%o and 2% morphine solutions in an open trial. The results showed a significant decrease in the duration of pain, the intensity as well as a decrease the need for systemic analgesia in the group with morphine mouthwash. No systemic clinically relevant adverse effects were noted. Hypothesis: Mouthwashes with a morphine containing solution decrease oral pain substantially, while not causing the side effects seen in systemic administration of narcotic analgesics. Method: A randomised double-blind cross-over study to evaluate the effect of topical oral application of a 0.2% morphine solution in patients suffering from radio- and/or chemotherapy induced oral mucositis. 60 patients will be included. Randomly assigned to either the morphine solution or a placebo mouthwash, they receive the first three days one of the solutions and then are switched over to the other treatment for three more days. General basic oral care is offered to all of the patients. Efficacy of treatment will be measured with a self-assessment pain scale. Doses of systemic opioids and other symptoms (appetite, dysphagia) will also be measured. If patient's don't receive systemic opioids, serum concentrations of morphine will be measured.